Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
ChemoMetec A/S
ChemoMetec makes machines and supplies that count and analyze cells automatically for drug, biotech, veterinary, and food companies.
ChemoMetec makes the machines and tiny plastic slides that let scientists count cells without peering down a microscope and tallying them by hand. A lab technician mixes a small sample with a stain, loads it into a slide, and the machine snaps pictures and uses software to count and sort the cells in minutes. That sounds like a small job, but cell counting is one of the most repeated chores in any biology lab, and it has to be right. If you start a batch of medicine with the wrong number of cells, the whole batch can be ruined.
Its customers are companies that grow cells on purpose: drugmakers, biotech labs, makers of veterinary vaccines, and food and beverage producers who need to check what is growing in their products. The classic way to count cells is to squint into a microscope and mark tally counters, which is slow and depends on who is doing the counting. ChemoMetec's pitch is that a machine gives the same answer every time, whether it's Tuesday morning or 2 a.m., and whether the person operating it has ten years of experience or ten days. The company sells the instrument once and then the consumable slides over and over, which is a nice business because lab budgets are sticky: once a method is written into a procedure, people don't switch. The company is headquartered in Allerød, a small town north of Copenhagen, and its shares trade on Nasdaq Copenhagen. It has long been known for fat profit margins, since the instruments are specialized and the slides are consumables customers must keep buying. The obvious risk is competition. Big lab-equipment names such as Thermo Fisher Scientific and Agilent Technologies and Danaher sell their own cell-analysis gear, and cheaper handheld counters chase the low end. ChemoMetec's defense is precision and the paper trail regulators like.
One interesting wrinkle: ChemoMetec's business is partly tied to the health of the biotech funding cycle. When investors pour money into young drug companies, those labs buy instruments and slides. When funding dries up and small biotechs cut spending or go under, the consumable orders shrink too. That is why a tiny Danish toolmaker can feel the mood of global biotech investors in its quarterly numbers. It is a quiet, profitable niche company whose fortunes swing with how generously the world is funding the search for new medicines.
Saved answer · last researched 12 Nov 2026